3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Osteosarcoma
2
Stomach Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Lung Neoplasms
1
Hepatoblastoma
1
Fibrolamellar hepatocellular carcinoma
1
Esophageal Neoplasms
1
Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Medullary
1
Carcinoma, Hepatocellular
1
Adenocarcinoma Of Esophagus
1
Interventions
Fluorouracil
9
Radiotherapy
8
Cisplatin
7
Paclitaxel
5
Oxaliplatin
5
Leucovorin
4
Irinotecan
4
Cetuximab
3
Surgical Procedures, Operative
2
Filgrastim
2
Docetaxel
2
uridine triacetate
1
pegylated granulocyte colony-stimulating factor, human
1
pegfilgrastim
1
dehydroftorafur
1
Sorafenib
1
Radiation
1
Polymerase Chain Reaction
1
Platinum
1
Granulocyte Colony-Stimulating Factor
1
Gemcitabine
1
Folfox protocol
1
Drug Therapy
1
Chemotherapy, Adjuvant
1
Capecitabine
1
Amplified Fragment Length Polymorphism Analysis
1
AMG 337
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NETWORK
×
Adenocarcinoma Of Esophagus
×
Sorafenib
×
Clear all
NCT01158287
2014-12-31
Sorafenib. ICORG 06-41, V4
Cancer Trials Ireland
Phase 2
Completed
54 enrolled